Cornell University

Cold Spring Harbor Laboratory

Vivek Mittal

Shahin Rafii

Albert S Mellick

Seongho Ryu

Maureen Lane

Daniel J Nolan

Linda Vahdat

Rakhi Naik

Dingcheng Gao

Methods of determining cancer progression or cancer relapse in a subject at risk for cancer progression or cancer relapse, the methods comprising: obtaining a sample from said subject; measuring the level of VEGFR1hematopoietic progenitor cells (HPCs) and/or VEGFR2endothelial progenitor cells (EPCs) in said sample; and taking additional samples and conducting additional measurements of HPCs and/or EPCs at one or more later time points. From the measurements, it can be determined whether there is a surge in the level of HPCs and/or EPCs in at least one later measurement, relative to an earlier measurement. A surge in the level of HPCs and/or EPCs indicates increased risk of progression or relapse of said subject's cancer.

Bone marrow-derived hematopoietic progenitor cells and endothelial progenitor cells as prognostic indicators for cancer

As described herein, increased expression of microRNA-708 reduces migration and metastasis of cancer cells.

Inhibiting migration of cancer cells

This invention provides methods of treating tumors and other conditions characterized by abnormal neoangiogenesis by inhibiting bone marrow-derived endothelial progenitor cells.

Treatment of tumors by ablating bone marrow-derived endothelial progenitor cells

Growing community of inventors

Greenlawn, NY, United States of America

Vivek Mittal